行情

IMMU

Immunomedics
IMMU
NASDAQ
已退市
市盈率(FWD)
市销率
市净率
市值
-47.6258
895.25
34.20
20,309,431,352.12
新闻
财报
公告
公司事件
分析
简况
Gilead Sciences Closes Immunomedics Purchase
finviz · 2020/10/23 15:47
Gilead Sciences Completes $21B Acquisition Of Immunomedics, Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (NASDAQ:IMMU) for approximately $21 billion in the aggregate. "We
Benzinga · 2020/10/23 13:17
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 2020/10/23 11:26
Gilead’s Sales Will Slip Even With Remdesivir, Says Analyst
Citigroup analyst Mohit Bansal rates Gilead stock at Buy but lowered his target price to $75 from $80. He sees two more years of revenue decline.
Barrons.com · 2020/10/22 13:58
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 21)
Benzinga · 2020/10/22 11:52
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 2020/10/21 12:04
The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19)
Benzinga · 2020/10/20 12:17
ProteoNic Announced Licensing of Technology for Production of Biologics to Immunomedics; Financial Details Not Disclosed
ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU)
Benzinga · 2020/10/20 09:42
更多
财务预测
每股收益每股净资产每股现金流
实际值（美元）
预测值（美元）
利润表更多
净利润营业总收入营业利润
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流（美元）
同比（%）
了解IMMU最新的财务预测，通过IMMU每股收益，每股净资产，每股现金流等数据分析Immunomedics近期的经营情况，然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测IMMU价格均价为75.77，最高价位88.00，最低价为47.60。
EPS
机构持股
总机构数: 393
机构持股: 2.37亿
持股比例: 102.42%
总股本: 2.31亿
类型机构数股数
增持
89
3,708.64万
建仓
138
1,843.91万
减持
82
2,691.69万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chairman/Executive Director
Behzad Aghazadeh
Chief Financial Officer
Usama Malik
Chief Human Resource Officer
Kurt Andrews
Chief Accounting Officer
William Fricker
General Counsel/Secretary
Jared Freedberg
Executive Director
Scott Canute
Other
Bryan Ball
Other
Brendan Delaney
Other
Loretta Itri
Independent Director
Robert Azelby
Independent Director
Charles Baum
Independent Director
Barbara Duncan
Independent Director
Peter Hutt
Independent Director
Khalid Islam
  • 分红
  • 拆股
  • 内部人交易
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取

微牛提供Immunomedics(NASDAQ-IMMU)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IMMU股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMMU股票基本功能。